{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:07:32Z","timestamp":1759342052893,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"publisher","award":["JP24591626"],"award-info":[{"award-number":["JP24591626"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Agency for Medical Research and development, AMED","award":["17ek0109098","17ek0109124"],"award-info":[{"award-number":["17ek0109098","17ek0109124"]}]}],"content-domain":{"domain":["clinicalkey.jp","jdsjournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jdermsci.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T04:14:58Z","timestamp":1517372098000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors"],"prefix":"10.1016","volume":"90","author":[{"given":"Kazuyasu","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Jimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Idogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kanekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2018.01.002_bib0005","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid: SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0015","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0020","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0025","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1073\/pnas.0913912107","article-title":"HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy","volume":"107","author":"Khan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/cdd.2013.47","article-title":"A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors","volume":"20","author":"New","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jprot.2011.11.010","article-title":"Proteomic study identified HSP 70\u202fkDa protein 1A as a possible therapeutic target in combination with histone deacetylase inhibitors, for lymphoid neoplasms","volume":"75","author":"Fujii","year":"2012","journal-title":"J. Proteom."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0040","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1093\/emboj\/17.21.6124","article-title":"Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases","volume":"17","author":"Jaattela","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0045","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0959-8049(97)00002-6","article-title":"Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients","volume":"33","author":"Santarosa","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0050","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0046-8177(98)90412-9","article-title":"Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy","volume":"29","author":"Trieb","year":"1998","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0055","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.1158\/1078-0432.CCR-08-0376","article-title":"Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0060","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2010.08126.x","article-title":"Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585","volume":"149","author":"St\u00fchmer","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0065","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1124\/mol.106.027912","article-title":"Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain","volume":"70","author":"Faraco","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0070","doi-asserted-by":"crossref","first-page":"523481","DOI":"10.1155\/2011\/523481","article-title":"Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock","volume":"2011","author":"Li","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0075","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1038\/bcj.2011.28","article-title":"Antileukemic activity of the HSP70 inhibitor pifithrin-mu in acute leukemia","volume":"1","author":"Kaiser","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0080","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.onc.1201704","article-title":"BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability","volume":"16","author":"Brimmell","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0085","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/sj.onc.1208495","article-title":"Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents","volume":"24","author":"Gabai","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2012.01.030","article-title":"Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells","volume":"321","author":"Yang","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2016.05.002","article-title":"Protection of stromal cell-derived factor 2 by heat shock protein 72 prevents oxaliplatin-induced cell death in oxaliplatin-resistant human gastric cancer cells","volume":"378","author":"Takahashi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0100","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ijc.11653","article-title":"Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes","volume":"108","author":"Faure","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0105","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/emboj\/17.6.1675","article-title":"Two CD95 (APO-1\/Fas) signaling pathways","volume":"17","author":"Scaffidi","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","article-title":"Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis","volume":"94","author":"Li","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0115","doi-asserted-by":"crossref","first-page":"33447","DOI":"10.1074\/jbc.M109.032359","article-title":"Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells","volume":"284","author":"Shawgo","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0120","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1074\/jbc.M107942200","article-title":"Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70","volume":"277","author":"Johnson","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0125","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/01.RES.0000338570.27156.84","article-title":"Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy","volume":"103","author":"Kee","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0130","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2010.10.014","article-title":"Targeting heat shock proteins in cancer","volume":"332","author":"Jego","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0140","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1073\/pnas.97.14.7871","article-title":"Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2","volume":"97","author":"Nylandsted","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2018.01.002_bib0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.2000.tb05605.x","article-title":"Heat shock protein 70 is required for the survival of cancer cells","volume":"926","author":"Nylandsted","year":"2000","journal-title":"Ann. N Y Acad. Sci."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181118300185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181118300185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T04:45:27Z","timestamp":1565325927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181118300185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0923181118300185"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2018.01.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"type":"print","value":"0923-1811"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}